wook,in addition to PIII good results in bulky,metastasized,incurable cancers...a disease which I doubt will ever see much Bavi application, a huge stimulus to PPHM stock price will be the first "spin-off" use...and even pre-clinical data would do it...such as Bavi use with rheumatoid, Alzheimers, or other inflammatory states. Inflammatory states seem a natural application for an immunological adjunct to be used alone or in combination with other anti-inflammatory agents or antibiotics. This is an arena PPHM should consider licensing.
News 
Market Data 
Discover 
AI
